Other Events ·
RedHill Biopharma is actively discussing potential collaborations to advance its investigational SPHK2 inhibitor…
RDHLRedHill Biopharma Ltd.
RedHill Biopharma is actively discussing potential collaborations to advance its investigational SPHK2 inhibitor, opaganib, for the treatment of Ebola virus disease, including potential involvement in the WHO’s SOLIDARITY CORE clinical trial platform. The company cited clinical data from a Phase 3 severe COVID-19 trial where opaganib demonstrated a 70.2% mortality reduction when administered as an add-on to the standard of care.